REDHILL BIOPHARMA LTD-SP ADR (RDHL) Fundamental Analysis & Valuation
NASDAQ:RDHL • US7574683014
Current stock price
0.8251 USD
-0.01 (-0.72%)
Last:
This RDHL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RDHL Profitability Analysis
1.1 Basic Checks
- RDHL had negative earnings in the past year.
- RDHL had a negative operating cash flow in the past year.
- In the past 5 years RDHL reported 4 times negative net income.
- In the past 5 years RDHL always reported negative operating cash flow.
1.2 Ratios
- RDHL has a worse Return On Assets (-45.00%) than 60.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)4.28%
ROA(5y)-16.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of RDHL (60.31%) is better than 69.27% of its industry peers.
- In the last couple of years the Gross Margin of RDHL has remained more or less at the same level.
- The Profit Margin and Operating Margin are not available for RDHL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.31% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.56%
GM growth 5Y-1.2%
2. RDHL Health Analysis
2.1 Basic Checks
- RDHL does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, RDHL has more shares outstanding
- RDHL has more shares outstanding than it did 5 years ago.
- RDHL has a better debt/assets ratio than last year.
2.2 Solvency
- RDHL has an Altman-Z score of -34.57. This is a bad value and indicates that RDHL is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -34.57, RDHL is doing worse than 89.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -34.57 |
ROIC/WACCN/A
WACC8.29%
2.3 Liquidity
- RDHL has a Current Ratio of 0.56. This is a bad value and indicates that RDHL is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Current ratio of RDHL (0.56) is worse than 90.10% of its industry peers.
- A Quick Ratio of 0.42 indicates that RDHL may have some problems paying its short term obligations.
- RDHL has a Quick ratio of 0.42. This is amonst the worse of the industry: RDHL underperforms 89.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.56 | ||
| Quick Ratio | 0.42 |
3. RDHL Growth Analysis
3.1 Past
- RDHL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.30%.
- Looking at the last year, RDHL shows a very strong growth in Revenue. The Revenue has grown by 23.17%.
- Measured over the past years, RDHL shows a small growth in Revenue. The Revenue has been growing by 5.04% on average per year.
EPS 1Y (TTM)-100.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)23.17%
Revenue growth 3Y-54.57%
Revenue growth 5Y5.04%
Sales Q2Q%58.59%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- RDHL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.22% yearly.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year82.69%
Revenue Next 2Y55.97%
Revenue Next 3Y45.22%
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. RDHL Valuation Analysis
4.1 Price/Earnings Ratio
- RDHL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. RDHL Dividend Analysis
5.1 Amount
- RDHL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
RDHL Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:RDHL (4/10/2026, 8:00:01 PM)
0.8251
-0.01 (-0.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-16 2024-09-16
Earnings (Next)N/A N/A
Inst Owners9.77%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap4.22M
Revenue(TTM)8.04M
Net Income(TTM)-8.27M
Analysts82.86
Price TargetN/A
Short Float %150.54%
Short Ratio0.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.52 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.47
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS1.57
BVpS-0.86
TBVpS-1.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.31% | ||
| FCFM | N/A |
ROA(3y)4.28%
ROA(5y)-16.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.56%
GM growth 5Y-1.2%
F-Score4
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 3.25% | ||
| Cap/Sales | 0.15% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.56 | ||
| Quick Ratio | 0.42 | ||
| Altman-Z | -34.57 |
F-Score4
WACC8.29%
ROIC/WACCN/A
Cap/Depr(3y)1.49%
Cap/Depr(5y)123.93%
Cap/Sales(3y)0.2%
Cap/Sales(5y)16.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)23.17%
Revenue growth 3Y-54.57%
Revenue growth 5Y5.04%
Sales Q2Q%58.59%
Revenue Next Year82.69%
Revenue Next 2Y55.97%
Revenue Next 3Y45.22%
Revenue Next 5YN/A
EBIT growth 1Y-215.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y68.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.74%
OCF growth 3YN/A
OCF growth 5YN/A
REDHILL BIOPHARMA LTD-SP ADR / RDHL Fundamental Analysis FAQ
What is the fundamental rating for RDHL stock?
ChartMill assigns a fundamental rating of 1 / 10 to RDHL.
What is the valuation status of REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?
ChartMill assigns a valuation rating of 0 / 10 to REDHILL BIOPHARMA LTD-SP ADR (RDHL). This can be considered as Overvalued.
Can you provide the profitability details for REDHILL BIOPHARMA LTD-SP ADR?
REDHILL BIOPHARMA LTD-SP ADR (RDHL) has a profitability rating of 1 / 10.
Can you provide the financial health for RDHL stock?
The financial health rating of REDHILL BIOPHARMA LTD-SP ADR (RDHL) is 0 / 10.